Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Lpathomab in Healthy Volunteers
NCT02341508Phase 1Completed
- Sponsor
- Lpath Therapeutics
- Start
- Sep 2015
- Primary completion
- Mar 2016
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lpathomab in neuropathic pain (6 arms), sponsored by Lpath Therapeutics. Primary endpoint: Proportion of patients with local or systemic Adverse Events at 85 days. Started Sep 2015; status: completed.
02
Drugs
lpathomab
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT02341508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341508.